Skip to content

To evaluate the effect of different timing of continuous renal replacement therapy on the prognosis of acute renal injury after acute aortic dissection

To evaluate the effect of different timing of continuous renal replacement therapy on the prognosis of acute renal injury after acute aortic dissection

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021935
Enrollment
Unknown
Registered
2019-03-16
Start date
2019-04-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute renal injury after acute type A of acute aortic dissection

Interventions

Early RRT group:the initiation of RRT will be permitted within 6 hours of diagnosis of KDIGO stage 2
Delayed RRT group:the initiation of RRT will be permitted within 8 hours of diagnosis of KDIGO stage 3 or absolute indications for RRT

Sponsors

Beijing Anzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18-70 years; (2) The operation was performed within 1 week after acute type A of aortic dissection (3) KDIGO classification stage 2 defined by at least one of the following criteria2-fold increase in serum creatinine from baseline(we used the serum creatinine at hospital admission as baseline serum creatinine) or urinary output = 12 hours; (4) Plasma neutrophil gelatinase–associated lipocalin (NGAL) > 150 ng/mL; (5) Required ICU treatment for at least 3 days.

Exclusion criteria

Exclusion criteria: (1) Pre-existing chronic renal failure (estimated glomerular filtration rate [eGFR] <30 mL/min); (2) previous renal replacement therapy; (3) cardiac arrest without awakening; (4) moribund with expected death within 24 hours; (5) prior renal transplant; (6) pregnancy; (7) hepatorenal syndrome; (8) AKI caused by obstructive etiology; (9) the patient refused clinical trial.

Design outcomes

Primary

MeasureTime frame
IL-6;IL-18;IGFBP7;NGAL;

Secondary

MeasureTime frame
lactic acid;

Countries

China

Contacts

Public ContactLiu Nan

Critical Care Unit of Cardiac Surgery, Beijing Anzhen Hospital

654974509@qq.com+86 13601233702

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026